Business Description
CNS Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US18978H2013
Share Class Description:
CNSP: Ordinary SharesDescription
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.82 | |||||
| Equity-to-Asset | -2.61 | |||||
| Debt-to-Equity | -0.07 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 16.3 | |||||
| 3-Year EPS without NRI Growth Rate | 16.4 | |||||
| 3-Year FCF Growth Rate | 17.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.87 | |||||
| 9-Day RSI | 45.17 | |||||
| 14-Day RSI | 39 | |||||
| 6-1 Month Momentum % | -85.38 | |||||
| 12-1 Month Momentum % | -84.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.26 | |||||
| Quick Ratio | 0.26 | |||||
| Cash Ratio | 0.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -98.4 | |||||
| Shareholder Yield % | -97.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1192.2 | |||||
| ROA % | -304.55 | |||||
| ROIC % | -3257.08 | |||||
| ROC (Joel Greenblatt) % | -448523.81 | |||||
| ROCE % | -1191.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-FCF | -0.15 | |||||
| Earnings Yield (Greenblatt) % | -909.09 | |||||
| FCF Yield % | -601.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNSP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CNS Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.575 | ||
| Beta | 0.21 | ||
| Volatility % | 147.2 | ||
| 14-Day RSI | 39 | ||
| 14-Day ATR ($) | 0.026289 | ||
| 20-Day SMA ($) | 0.217714 | ||
| 12-1 Month Momentum % | -84.77 | ||
| 52-Week Range ($) | 0.19 - 2.98 | ||
| Shares Outstanding (Mil) | 10.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CNS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CNS Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CNS Pharmaceuticals Inc Frequently Asked Questions
What is CNS Pharmaceuticals Inc(CNSP)'s stock price today?
The current price of CNSP is $0.22. The 52 week high of CNSP is $2.98 and 52 week low is $0.19.
When is next earnings date of CNS Pharmaceuticals Inc(CNSP)?
The next earnings date of CNS Pharmaceuticals Inc(CNSP) is 2024-05-15 Est..
Does CNS Pharmaceuticals Inc(CNSP) pay dividends? If so, how much?
CNS Pharmaceuticals Inc(CNSP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers